arrow
C

Chaiyut Charoentum

faculty of medicine of chiang mai university
H指数:11
被引数:1,018

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gemcitabine plus cisplatin versus gemcitabine as adjuvant therapy after curative-intent resection of cholangiocarcinoma (GeCiCCA): a multicenter, randomized controlled, phase III trial

吉西他滨联合顺铂与吉西他滨单药作为根治性切除术后胆管癌辅助治疗的比较(GeCiCCA):一项多中心、随机对照、III期临床试验

2026-11-060
OAAI
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer

评估MARIPOSA研究中非小细胞肺癌患者症状进展时间这一患者相关的疗效终点

2026-07-090
OA
Machine learning–based cfDNA fragmentation profiling using automated capillary electrophoresis for early detection of hepatocellular carcinoma

基于机器学习的cfDNA片段化谱分析,采用自动化毛细管电泳进行肝细胞癌的早期检测

2026-02-170
OA
Development of A Risk Assessment Model for Venous Thromboembolism among Patients with Cholangiocarcinoma

胆管癌患者静脉血栓栓塞风险评估模型的开发

2026-01-010
PRE
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer

MAGELLAN方案B1和B3臂:在治疗初治转移性非小细胞肺癌患者中,比较度伐利尤单抗联合化疗与联合化疗并联合奥雷oclumab的疗效。

2025-11-070
PRE
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase 2 trial

Savolitinib 联合 Osimertinib 治疗表皮生长因子突变、MET 扩增的晚期非小细胞肺癌:一项随机 II 期临床试验

2025-10-220
PRE
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study

FGFR2融合或重排在年轻肝内及肝门部胆管癌患者中的关键遗传学见解:一项泛亚洲研究

2025-09-160
OAAI
Efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): a multicenter, phase II clinical trial

吗替麦考酚酯在局部晚期或转移性骨肉瘤(ESMMO)患者中的有效性和安全性:一项多中心、II期临床试验

2025-09-120
PRE
The efficacy of premedication with 10 mg versus 20 mg of intravenous dexamethasone for prevention of paclitaxel hypersensitivity reaction in low-risk gynecologic cancer patients: a non-inferiority, randomized controlled mono-institutional trial

10 mg与20 mg静脉注射地塞米松预处理预防低风险妇科癌症患者紫杉醇超敏反应的疗效:一项非劣效性、随机对照单中心试验

2025-08-250
PRE
Positivity rates of FGFR2 fusion gene or rearrangement and genetic profiling in Asian Cholangiocarcinoma

FGFR2融合基因或重排的阳性率及亚洲胆管癌的基因谱分析

2024-12-011
PRE
Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
2024-04-050
PRE
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
2021-04-2919
OAAI